NZ619207A - Method of treating a mammalian teat and related compositions - Google Patents
Method of treating a mammalian teat and related compositionsInfo
- Publication number
- NZ619207A NZ619207A NZ619207A NZ61920712A NZ619207A NZ 619207 A NZ619207 A NZ 619207A NZ 619207 A NZ619207 A NZ 619207A NZ 61920712 A NZ61920712 A NZ 61920712A NZ 619207 A NZ619207 A NZ 619207A
- Authority
- NZ
- New Zealand
- Prior art keywords
- topical composition
- alcohol
- citrate
- teat
- topical
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 210
- 230000000699 topical Effects 0.000 claims abstract description 77
- 229940042115 Methylene blue Drugs 0.000 claims abstract description 55
- 229960000907 methylthioninium chloride Drugs 0.000 claims abstract description 55
- -1 alkyl para-hydroxybenzoate Chemical compound 0.000 claims abstract description 52
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 40
- 210000003491 Skin Anatomy 0.000 claims abstract description 32
- 229920000642 polymer Polymers 0.000 claims abstract description 28
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 18
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 18
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 15
- 230000002633 protecting Effects 0.000 claims abstract description 15
- 229920000728 polyester Polymers 0.000 claims abstract description 8
- 238000005336 cracking Methods 0.000 claims abstract description 5
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims abstract description 5
- 208000004396 Mastitis Diseases 0.000 claims abstract description 4
- 229920002689 polyvinyl acetate Polymers 0.000 claims abstract description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims abstract description 4
- 238000001035 drying Methods 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims abstract 14
- 239000011253 protective coating Substances 0.000 claims abstract 3
- JNXDCMUUZNIWPQ-UHFFFAOYSA-N trioctyl benzene-1,2,4-tricarboxylate Chemical compound CCCCCCCCOC(=O)C1=CC=C(C(=O)OCCCCCCCC)C(C(=O)OCCCCCCCC)=C1 JNXDCMUUZNIWPQ-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 239000003974 emollient agent Substances 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000002562 thickening agent Substances 0.000 claims description 14
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 11
- 230000000845 anti-microbial Effects 0.000 claims description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 239000000499 gel Substances 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 8
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 229960002216 methylparaben Drugs 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000004328 sodium tetraborate Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 230000001681 protective Effects 0.000 claims description 4
- 239000004166 Lanolin Substances 0.000 claims description 3
- 229940039717 Lanolin Drugs 0.000 claims description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 150000001642 boronic acid derivatives Chemical group 0.000 claims 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 101700082413 tant Proteins 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 210000002445 Nipples Anatomy 0.000 description 86
- CXKWCBBOMKCUKX-UHFFFAOYSA-M Methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 41
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 230000001603 reducing Effects 0.000 description 17
- 238000006722 reduction reaction Methods 0.000 description 17
- 239000003349 gelling agent Substances 0.000 description 14
- 244000005700 microbiome Species 0.000 description 13
- 235000013365 dairy product Nutrition 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 12
- 229940076185 Staphylococcus aureus Drugs 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000004599 antimicrobial Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 150000001860 citric acid derivatives Chemical class 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 229920001888 polyacrylic acid Polymers 0.000 description 6
- 230000003115 biocidal Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000907138 Xanthomonas oryzae pv. oryzae Species 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000005187 foaming Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 210000000481 Breast Anatomy 0.000 description 3
- 229940035295 Ting Drugs 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 230000002421 anti-septic Effects 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 150000004684 trihydrates Chemical class 0.000 description 3
- 239000011778 trisodium citrate Substances 0.000 description 3
- 235000019263 trisodium citrate Nutrition 0.000 description 3
- 229940038773 trisodium citrate Drugs 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 2
- 229940064004 Antiseptic throat preparations Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229960001631 Carbomer Drugs 0.000 description 2
- 241001508000 Corynebacterium bovis Species 0.000 description 2
- 229920000896 Ethulose Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 229920000126 Latex Polymers 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229940030998 Streptococcus agalactiae Drugs 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000565 sealant Substances 0.000 description 2
- VQOIVBPFDDLTSX-UHFFFAOYSA-M sodium;3-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1 VQOIVBPFDDLTSX-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- ZQBJRVYLUFBBEQ-UHFFFAOYSA-N 2-[diamino(3-formamidopropyl)azaniumyl]acetate Chemical compound [O-]C(=O)C[N+](N)(N)CCCNC=O ZQBJRVYLUFBBEQ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-Hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 240000005513 Aloe vera Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 229940047648 COCOAMPHODIACETATE Drugs 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H Calcium citrate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940113118 Carrageenan Drugs 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 240000005497 Cyamopsis tetragonoloba Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 229960003949 Dexpanthenol Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229960000633 Dextran Sulfate Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010020648 Hyperkeratosis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- WQYVRQLZKVEZGA-UHFFFAOYSA-N Hypochlorite Chemical class Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940035535 Iodophors Drugs 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000282322 Panthera Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K Potassium citrate Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 229940057910 Shea butter Drugs 0.000 description 1
- 229940096501 Sodium Cocoamphoacetate Drugs 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N Sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N Xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004287 bisbiguanides Chemical class 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000001680 brushing Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZZRCKSSPGJOTEE-UHFFFAOYSA-L disodium;carbamoyl phosphate Chemical compound [Na+].[Na+].NC(=O)OP([O-])([O-])=O ZZRCKSSPGJOTEE-UHFFFAOYSA-L 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001329 hyperkeratotic Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000003020 moisturizing Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- HFQBFCSVHWJVNK-UHFFFAOYSA-N sodium;2-[1-(2-hydroxyethyl)-2-undecyl-4,5-dihydroimidazol-1-ium-1-yl]acetate Chemical compound [Na+].CCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O HFQBFCSVHWJVNK-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000011791 tripotassium citrate Substances 0.000 description 1
- 235000015870 tripotassium citrate Nutrition 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
Disclosed is the use of a topical composition comprising (a) citrate; (b) methylene blue; and (c) an alkyl para-hydroxybenzoate; in the manufacture of a medicament for treating or protecting against mastitis or drying, chapping, or cracking of the skin of a mammalian teat. Also disclosed is a two-part topical composition comprising: (a) a first topical composition comprising a polymer; and (b) a second topical composition comprising a cross-linking agent for the polymer; whereby a protective coating is provided when applied to a non-human teat; wherein the polymer comprises polyvinyl alcohol, polyvinyl acetate, N-alkyl pyrrolidone, polyester phthalate, polyester sebacat, or trioctyl trimellitate; and wherein the first or second topical composition, or both, comprises methylene blue. art topical composition comprising: (a) a first topical composition comprising a polymer; and (b) a second topical composition comprising a cross-linking agent for the polymer; whereby a protective coating is provided when applied to a non-human teat; wherein the polymer comprises polyvinyl alcohol, polyvinyl acetate, N-alkyl pyrrolidone, polyester phthalate, polyester sebacat, or trioctyl trimellitate; and wherein the first or second topical composition, or both, comprises methylene blue.
Description
METHOD OF TREATING A MAMMALIAN TEAT
AND RELATED COMPOSITIONS
CROSS REFERENCE TO RELATED ATIONS
This application claims priority to US. Provisional Patent ation No.
,053 filed on May 27, 2011.
BACKGROUND OF THE INVENTION
Care and maintenance of the teats and udders of dairy animals is essential in order
to t damage to the animals and economic loss to the dairy farmer. Infections of the
teats of dairy animals, such as mastitis, can result in increased veterinary costs, loss of milk
production, and, in serious cases, death of the dairy animal. One approach to caring for the
teats and udders of dairy animals is the application of topical compositions to the teats and
udders in order to maintain skin quality and reduce infections. However, there continues to
be a need for new, effective methods and compositions useful for this purpose.
BRIEF SUMMARY OF THE INVENTION
Provided herein is a method of treating or protecting a mammalian teat.
According to one aspect, the method comprises applying a topical composition to the teat,
wherein the topical composition comprises (a) citrate; (b) methylene blue; and (c) an alkyl
para—hydroxybenzoate. According to another , the method comprises applying to the
teat a first l ition comprising a polymer, and a second topical composition
comprising a cross—linking agent for the polymer, whereby a protective g is provided on
the teat. The first or second itions, or both, optionally r comprise citrate,
methylene blue, or alkyl para-hydroxybenzoate.
Compositions useful in the above methods, or for other purposes, also are provided
herein. In one aspect, a composition is provided, which comprises (a) about 0.1—2 M citrate;
(b) about 0.1—1 mM methylene blue; (0) about 10—50 mM alkyl para—hydroxybenzoate; ((1)
about 0.1% to about 20% alcohol; and (e) about 5 wt.% or more emollient. In another aspect,
a composition is provided that comprises (a) about 0.1—2 M citrate; (b) about 0.1—] mM
methylene blue; (0) about 10—50 mM alkyl para—hydroxybenzoate; ((1) about 20% to about
80% alcohol; and (e) a gelling agent. Also, compositions ed for sequential or
simultaneous use are provided, as well as a kit comprising the individual compositions, is
provided herein. One such composition comprises (a) e; (b) about 0.1—1 mM methylene
blue; and (0) about 5—50 wt.% polymer. r such composition comprises (a) about 0.1—2
M citrate; (b) about 20—100 mM alkyl para-hydroxybenzoate; (0) about l—lO% alcohol; and
(d) a cross-linking agent.
DETAILED DESCRIPTION OF THE INVENTION
Provided herein is a method of treating or protecting a mammalian teat by
applying particular topical compositions to the teat. By “treat or protect,” it is meant that the
composition once applied maintains or improves the health or ion of the teat,
cally the health or condition of the skin of the teat. Without intending to limit the
mechanism of action,
scope of the subject matter described herein to any ular theory or
it is believed the topical compositions described herein treat or protect the skin of the teat as a
result of the antimicrobial properties of the composition, the emollient or protective barrier-
forming properties of the composition, or some combination thereof.
According to one aspect, the topical composition comprises (a) citrate; (b)
ene blue; and (c) an alkyl para-hydroxybenzoate. Any suitable amount of citrate,
methylene blue, and alkyl para—hydroxybenzoate can be used, provided the composition
retains the ability to treat or protect a mammalian teat. Without wishing to be bound by any
particular theory, it is believed that the citrate, methylene blue, and alkyl—hydroxybenzoate
together provide an ed antimicrobial effect. Thus, in one embodiment, the
composition comprises each of these components in a concentration sufficient to exert an
crobial .
The methylene blue es the additional age of serving as a color
indicator, allowing for easy visual confirmation that the composition has been applied to a
skin surface. rmore, whereas staining of the teats of diary animals has been a concern,
it has surprisingly been found that the color of a methylene blue solution is oxidized as it
comes into contact with bacterial and, perhaps, as bacteria levels rise when re—application of
the composition is . Some embodiments of the ion, therefore, provide for a
method and composition that reduces or eliminates teat staining and provides, in some cases,
an indicator that re—treatment is needed.
In some embodiments, the composition comprises about 0.1 M or more citrate,
such as about 0.2 M or more, or about 0.3 M or more citrate. Typically, the composition will
comprise no more than about 2 M citrate, such as about 1 M or less, about 0.8 M or less, or
about 0.5 M or less. The foregoing amounts also can be expressed as ranges (e.g., about 0.1-
2 M, about 0.1—1 M, about 8 M, about 0.2-2 M, about 0.2—1 M, about 8 M, about
0.3—2 M, about 0.3—1 M, about 0.3-0.8 M, about 0.3-0.5 M). Any sub-range thereof also is
contemplated.
The citrate can be provided by any suitable source. For instance the citrate can be
provided by citric acid, a citrate salt, or a combination thereof. le salts include sodium,
potassium, ium, or calcium citrate salts. Furthermore, the citrate salt can be a
monvalent salt or a multivalent salt, such as a sic, dibasic, or tribasic citrate salt (e.g.
mono-, di-, or tri-sodium citrate or mono-, di—, or tri-potassium citrate).
_ [0009] In some embodiments, the composition comprises sodium, potassium,
magnesium, or m ions in a concentration of about 0.1 M or more, such as 0.2 M or
more, or even 0.3 M or more. The sodium, potassium, magnesium, or calcium ions can
provided by any suitable source, for instance, by use of sodium, potassium, magnesium, or
m citrate salts as a source for the citrate.
In some embodiments, the composition comprises about 0.1 mM or more
methylene blue, such as about 0.2 mM or more methylene blue, 0.5 mM or more methylene
blue, or even 0.8 mM or more methylene blue. Typically, the composition will comprise no
more than about 30 mM, or no more than about 10 mM, such as about 3 mM or less, about 2
mM or less, about 1 mM or less, about 0.8 mM or less, about 0.7 mM or less, or about 0.6
mM or less (e.g, about 0.5 mM or less) of methylene blue. The foregoing amounts also can
be expressed as ranges (e.g,. about 0.1—3 mM, about 0.1-2 mM about 0.1-1 mM, about 0.1—0.8
mM, about 0.1-0.7 mM, about 0.2-1 mM, about 0.2-0.8 mM, about 0.2—0.7 mM). Any sub-
range thereof also is contemplated.
In some embodiments, the composition comprises about 10 mM or more alkyl
para—hydroxybenzoate, such as about 12 InM or more, or about 15 mM or more. Typically,
the composition will se no more than about 60 mM or no more than about 50 mM
alkyl para—hydroxybenzoate, such as about 40 mM or less, about 30 mM or less, or about 25
mM or less alkyl para-hydroxybenzoate. The foregoing amounts also can be expressed as
about 12—40
ranges (e.g., about 10—50, about 10-30 mM, about 10-25 mM, about 12—50 mM,
mM, about 12—30 mM, about 12—25 mM, about 15-50 mM, about 15—40 mM, about 15—30
mM, about 15—25 mM). Any sub—range thereof also is contemplated.
Any alkyl ydroxybenzoate can be used. Suitable alkyl para—
hydroxybenzoates include —, ethyl-, propyl-, and butyl~para-hydroxybenzoate. The
composition can comprise more than one type of alkyl para—hydroxybenzoate. For example,
the composition can se methyl— and ethyl-para-hydroxybenzoate. When more than
within the
one type of alkyl para-hydroxybenzoate is used, the combined amount is lly
ranges discussed above. In one ment, the composition comprises about 1-3 mM (e.g.,
about 1—2 mM) of propyl-parahydroxybenzoate, and the remaining portion of the alkyl para-
hydroxybenzoate is methyl-para—hydroxybenzoate. The alkyl para—hydroxybenzoate can be
supplied by any source, for ce, a salt of an alkyl para-hydroxybenzoate or an alkyl
para~hydroxybenzoic acid.
The composition can further comprise an ent. Suitable emollients include,
for instance, glycerol, propylene glycol, lanolin, glycerin, sorbitol, D-panthenol, poly
ethylene glycol (PEG) (e.g., mw. ZOO—10,000) and esters thereof, acyl ates,
polyquaternium compounds (polyquaternium-7), glycerol e/laurate, PEG—7 glycerol
cocoate, stearic acid, hydrolyzed silk peptide, silk protein, aloe vera gel, guar
hydroxypropyltrimonium chloride, alkyl poly glucoside/glyceryl luarate, shea butter and coco
butter. In some embodiments, emollients will typically be present in an amount of about 5
wt.% or more, such as about 10 wt.% or more, or even about 15 wt.% or more. In some
embodiments, the ition will generally have no more than about 30 wt.% emollients,
such as about 25 wt.% or less, or even 20 wt.% or less. In other embodiments (e.g., cold-
weather formulations), more ent may be used, such as about 30 wt.% or more, about 40
wt.% or more, about 50 wt.% or more, or even about 60 wt.% or more or even about 75 wt.%
or more.
The composition can r comprise a barrier or film—forming agent, or a
thickener. Suitable barrier and film—forming agents and thickeners include, for instance,
polyvinylpyrrolidone (PVP), polyvinylalcohol (PVA or PVOH), polyacrylate,
polyacrylamide, latex, carbomer, glycerol, hemicelluloses (e.g., arabinoxylanes and
glucomannanes); plant gum materials (e. g., guar gum, gum arabic, and johannistree gums);
cellulose and derivatives thereof (e.g., methyl cellulose, ethyl cellulose, hydroxypropyl
cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose;
methylhydroxypropylcellulose (HPMC) and ethylhydroxyethylcellulose); starch and starch
derivatives (e.g, yethyl starch or cross linked ); microbial and sea weed
polysaccharides (e.g., xanthan gum, sodium alginate, carrageenan, curdlan, pullulan, and
dextran), dextran sulfate, whey, collagen, pectin, gelatin, chitosan, an derivatives, and
polysulfonic acids and their salts. Clays and modified clays (e. g., bentonite or laponite),
dal alumina or , and fatty acids or salts thereof can also be used as thickeners, co-
thickeners, or stability agents for thickeners. The amount used will depend upon the
ular agent selected. Generally, when used, the barrier or film forming agent, or
thickener, will be present in an amount of about 0.1 wt.% or more, such as about 1 wt.% or
more, 2 wt.% or more, 5 wt.% or more, or even 10 wt.% or more. Typically, the barrier or
film forming agent, or thickener, constitute no more than about 40 wt.% of the composition,
such as about 35 wt.% or less, 30 wt.% or less, or 25 wt.% or less.
In some embodiments, the composition comprises at least one gelling agent,
which can be the same as, or different from, the r or film-forming agent or ner.
Gelling agents include any of those agents described as above with respect to the barrier or
film—forming agents and thickeners that can produce a gel. By way of non-limiting
examples, the gelling agent can be polyvinylpyrrolidone (PVP), polyvinylalcohol (PVA or
PVOH), polyacrylate (e.g., cross—linked polyacrylic acid polymers such as the CARBOPOL®
products by Lubrizol Corp, or acrylate copolymer Capigel 98TM by Seppic, Inc.),
polyacrylamide, latex, carbomer, cellulose or derivative thereof (e. g., methyl cellulose, ethyl
cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, ymethyl cellulose,
yethyl cellulose; methylhydroxypropylcellulose (HPMC) and
ethylhydroxyethylcellulose). The amount used will depend upon the particular agent
selected. Generally, when used, the gelling agent will generally be present in an amount of
about 0.1 wt% or more, such as about 1 wt.% or more, about 2 wt.% or more, or even about 5
wt.% or more. Typically, the gelling agent will constitute no more than 0 wt.% or no
more than about 40 wt.% of the ition, such as about 35 wt.% or less, or 30 wt.% or
less. By way of further illustration, in some applications, the composition will comprise
about 1-50 wt.%, or about 1—20 wt.%, such as about 2—10 wt.% or even about 2—5 wt.%, of the
gelling agent. In other applications, the composition can comprise about 10—30 wt.% or 20—
wt.% gelling agent.
The composition can further se a surfactant or foaming agent. Surfactants
include anionic, cationic, ic, zwitterionic and amphoteric surfactants, and can be high
g, low foaming, moderate foaming,_or non foaming type surfactants. Anionic
surfactants include, for example, linear alkyl benzene sulfonic acid,linear alkyl benzene
sulfonate, alkyl sulfomethyl ester, Ot-Olefin ate, alcohol ether sulfate, alkyl sulfate,
alkylsulfo- and dialkylsulfo succinate, and salts thereof. Nonionic surfactants include, for
example, alkyl polyglucoside, alkyl ethoxylated alcohol, alkyl propoxylated alcohol,
ethoxylatedpropoxylated alcohol, henol ethoxylates, sorbitan, sorbitan ester, alkanol
amide, and polyethoxylated polyoxypropylene block copolymers (poloxamers). eric
surfactants include, for example, alkyl betaines and alkyl amphoacetates (e. g.,
cocoamidopropyl betaine, sodium cocoamphoacetate, sodium lauroamphoacetate and sodium
cocoamphodiacetate).
The principal carrier for the topical composition will typically be water.
Generally, the composition will comprise water in an amount of about 15 wt.% or more,
about 30 wt.% or more, or about 40 wt.% or more, such as about 60 wt.% or more, or even
70 wt.% or more (e.g., 80 wt.% or more).
The composition also can comprise an alcohol in any suitable amount. Any
alcohol can be used, including methanol, ethanol, anol, isopropanol (IPA), and the like.
According to some embodiments, the composition comprises lower alcohol concentrations,
such as about 0.1 wt.% to about 20 wt.% alcohol, such as about 1 wt.% to about 15 wt.%, or
even about 5 wt.% to about 10 wt.% alcohol. Low alcohol levels used in combination with
ents are believed to be especially useful for treating or ting a mammalian teat in
the milking season. A composition that is believed to be particularly ageous when
using a low alcohol content comprises (a) about 02—1 M e; (b) about 0.01—2 mM or
about 0.1~l mM methylene blue; (c) about 10-50 mM alkyl para—hydroxybenzoate; (d) about
0.1% to about 20% alcohol; and (e) about 5 wt.% or more of an emollient.
According to other embodiments, higher alcohol levels are used, such as about 20
wt.% or more, about 25 wt.% or more, about 30 wt.% or more, about 35 wt.% or more, about
40 wt.% or more, or even about 50 wt.% or more. Typically, no more than about 80%
alcohol is used, such as about 70% or less. Such embodiments are thought to be useful when,
for instance, a gelling agent is used so as to provide a formulation suitable for use as a teat
sealant for dairy mammals in the dry season. A composition ed to be particularly
advantageous when using a higher alcohol level comprises (a) about 0.2-1 M citrate; (b)
about 0.01—2 mM or about 0.1—1 mM methylene blue; (c) about 10—50 mM alkyl para-
hydroxybenzoate; (d) about 20% to about 80% alcohol; and (e) a gelling agent, such as a
polyacrylic acid or acrylate copolymer gelling agent.
ing to another aspect of the method, the composition can be formulated as
a rt composition. The method comprises applying to the teat a first topical
composition comprising a polymer, and a second topical ition comprising a cross-
linking agent for the polymer. When both the first and second compositions have been
applied to the teat, the polymer and cross—linking agent combine to form a film or gel, thereby
providing a tive coating on the teat. The two-part ation is believed to be
particularly effective as a teat sealant for use on the teats of dairy animals during the dry
season.
In the two—part formulation, the first or second compositions, or both, optionally
further comprise citrate, methylene blue, or alkyl para—hydroxybenzoate in the amounts
previously described. The first or second compositions also can comprise any of the other
components bed herein. By way of further illustration, the first ition can
se citrate, methylene blue, and a polymer, and the second composition can comprise
citrate, alkyl para—hydroxybenzoate, a linking agent, and, optionally, alcohol. The first
and second compositions can be used simultaneously or sequentially in any order. When
used sequentially, both compositions should be applied within a time frame that prevents
drying of the first—applied composition prior to application of the second-applied
composition. In other words, the composition that is applied first should still be wet when the
second composition is applied so as to facilitate interaction of the cross—linking agent with the
polymer and formation of a gel.
The particular polymer and cross linking agent selected will depend on the
intended end—use of the composition and the desired properties of the resulting cross-linked
gel. By way of illustration, the polymer can be PVA and the cross-linking agent can be a
borate, such as sodium borate (borax). Other suitable polymers and linking agents
include polyvinyl acetate, other vinyl monomers and polymers, N-alkyl pyrrolidone,
polyester phthalate, polyester sebacat, trioctyl litate and other chemicals known to
perform as plasticizers.
One composition that is ered to be particularly effective when used in a
two~part formulation comprises (a) citrate; (b) about 0.01-2 mM or about 0.1—1 mM
methylene blue; and (c) about 5—50 wt.% water soluble polymer. An effective complimentary
composition comprises (a) about 0.2-1 M citrate; (b) about 20-100 mM alkyl para-
hydroxybenzoate; (0) about l-lO% alcohol; and (d) a cross-linking agent. Although the
compositions are intended to be used together, either simultaneously or sequentially, they
should be ed and stored separately (e. g., in te containers, or in separate
rs of a single container) prior to use. Thus, in addition to the method and individual
itions, a kit is provided herein, which comprises (1) a first composition comprising (a)
citrate; (b) about 0.01—2 mM or about 0.1—1 mM methylene blue; and (0) about 5-50 wt.%
r, such as about 10-40 wt% or 20-30 wt.% polymer (e.g., PVA); and (2) a second
composition comprising (a) about 0.2—1 M citrate; (b) about 20-100 mM alkyl para—
hydroxybenzoate; (c) about l—lO% alcohol; and (d) a cross—linking agent in an amount
sufficient to e the desired gel consistency (e.g., borate or sodium borate in any amount,
such as about 1-5 wt.%) .
The itions described herein can have any suitable pH. Desirably, the
composition will have a pH that will not cause irritation or damage to the skin of a mammal,
particularly the skin of a ian teat. Thus, the composition will typically have a neutral
pH (e.g., about 4—8, about 5-8, or about 6—7). The pH can be adjusted by any suitable method.
For instance, the ratio of citrate to citric acid as a source of the citrate ion can be ed so
as to provide the desired pH. atively, or in addition, a pH adjuster and/or buffer can be
used to obtain the desired pH.
The compositions described herein can be formulated as a liquid, foam, or gel, and
topically d in any manner. For instance, the composition can be applied by dipping the
teat of a mammal into the composition, or by wiping, brushing, or spraying the composition
onto the skin of the teat. The compositions, especially liquid itions, can have any
suitable viscosity. In some instances, however, it may be desired to use a thicker ition
without
so that the composition is retained on the skin of the teat for a longer period of time
dripping. Thus, the composition can be formulated so as to have a higher viscosity, such as
about 50 cP or more, about 100 cp or more, about 200 cp or more, about 500 cP or more,
about 1000 cP or more, about 2500 cp or more, or even about 5000 cp or more. The viscosity
of the composition will lly be less than about 10,000 cp. Viscosity refers to the
kinematic viscosity measured at standard temperature and pressure (25 0C and 1 atm).
In preferred embodiments, the compositions described herein provide an
antimicrobial effect when applied to the skin of a mammal, especially the skin of the teat of a
dairy animal. As previously mentioned, it is believed that this effect is primarily the result of
the combined action of the citrate, methylene blue, and alkyl para—hydroxybenzoate, and
perhaps alcohol. The composition can further comprise additional antibiotic or antimicrobial
agents, particularly l antibiotic or antimicrobial agents, such as such as iodine—
containing antiseptics (e. g., iodine or iodophors); chlorine based antiseptics (e.g,
hypochlorites (e. g., sodium hypochlorite; anolyte); ptic plant oils; phenols; quaternary
ammonium compounds; ptic surfactants; bisbiguanides (e. g., chorhexidine); terpenes;
sodium onate; sulfates; guanidine salts; formaldehyde—releasing compounds; ascorbic
acid; and peracids/peroxides.
While the compositions described herein can be formulated with additional
antibiotic or antiseptic components, one of the advantages of at least some compositions
described herein is that such onal antibiotic or antiseptic agents are not required. Thus,
in additional embodiments, the compositions bed herein can be substantially free (e. g.,
contains less than an antimicrobial-effective amount) or completely free of one or more
common topical antibiotic or antiseptic agents, such as those mentioned above.
Alternatively, the compositions can be substantially free or completely free of any antiseptic
or antimicrobial agent other than citrate, methylene blue, alkyl para—hydroxybenzoate, and
alcohol.
The compositions described herein can be provided in any suitable container. In
one embodiment, the ner is an applicator suitable for applying the composition to the
skin of the teat of a dairy animal. Such an ator can comprise, for instance, a cup
portion of a size and shape that will allow the teat to be inserted into the cup and contact the
topical composition. When two—part compositions are used, the applicator can optionally
comprise two cup portions: a first cup portion containing a first ition, and a second
cup portion containing a second composition. Alternatively, a single cup portion with two
separate reservoirs might be used, wherein each reservoir contains one of the two topical
itions and each reservoir is fluidly connected to the cup n such that the
compositions can be delivered to the cup portion simultaneously or sequentially.
The methods and compositions described herein are useful with respect to any
type of mammal, particularly a food-producing mammal such as a dairy animal. The
methods and compositions described herein may be particularly useful for treating or
ting the teats of food—producing s susceptible to teat infections, such as
mastitis, and, thus, may be particularly useful in treating or protecting the teats of dairy cows.
Any composition as described above can be used in the method of treating or
protecting a mammalian teat, t limitation. rmore, each of the foregoing
compositions described in the context of the method of treating or ting a mammalian
teat is considered to be a separate aspect of the invention. Although these compositions have
been described in the t of a method of treating or protecting a mammalian teat, they are
not limited to any particular intended use, and have other practical applications, both in the
agricultural and dairy industries, and in other contexts. For instance, they can be used as
WO 66655
general antimicrobial compositions, skin and would cleansing compositions, protective
barrier film—forming compositions, and moisturizing compositions, especially for the skin of
humans and animals.
The following examples further illustrate the invention but, of , should not
be construed as in any way limiting its scope.
This example trates the crobial properties of compositions of the
invention.
Eight compositions (compositions l—8) were prepared using the components
fied in Table 1. Each composition was tested in vitro at six different concentrations to
determine the antimicrobial effect against four strains of bacteria: methicillin-sensitive
Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), and
two strains of E. 0011'. Tests were run in duplicate, and performed in accordance with the
procedures set forth in Clinical and Laboratory Standards Institute (CLSI) reference M—lOO.
The results are provided in Tables 2-9, wherein the minimum inhibitory concentration (MIC)
is the concentration required to inhibit visible growth of the microorganism, and the
m bactericidal concentration (MBC) is the concentration required to kill the
microorganism. The results show that the tested compositions had a substantial crobial
effect.
Table 1
Composition No.
Component 3 4 5 6 7 8
Trisodium
Citrate
Dihydrate, 1 0% 10% 10% 20% 10% 20% 10% 20%
Granular,
Citric Acid
Anhydrous,
0.11% 0.15% 0.14% 0.24% 0.14% 0.17% 0.13% 0.26%
Powder
Methylene
Blue
0.02% 0.01% 0.01% 0.01% 0.02% 0.01% 0.02% 0.01%
Trihydrate
Methyl—
n 0. 2% 0.3% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2%
paraben 0.02% 0.03% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02%
Isopropyl
% 5 0/o 1 0% 5% -— —- 5% 5%
Alcohol
Xanthan
0.45%
PVP K60
1 % --
Solution
Glycerol 3 0/o 3% 3% 3% 3% 3% 10% 8%
Propylene
2 0/o 2 0/0 2 0/o 2 0/o 2 0/o 2 0/o 3 . 8 0/o 2 C'/o
Glycol 1
Water 79.65% 79.51% 74.63% 69.53% 84.62% 74.60% 69.83% 64.07%
pH 6.5—7 6.4-6.8 9 6.5-6.8 6.4-6.7 6.5—6.9 6.5—6.8 6.5-6.7
*All amounts are expressed as weight percentages.
Table 2
l r
on (ug/ui) of Composition 1
{ 1/32 11/64 ‘1/128 Control
I # ) 4 ‘ 5 6 12 Organism MIC ‘ MBC
A * ‘ * * * “I “32qu/8
B * T* * * j MSSA
MSSA )
‘ C * * * * MRSA 1/32 1/8
‘ D * * * * MRSA
‘ E * * * * EC 1/8 1/8
F ,2 ‘ 3“ * * EC
G ‘ * * * * EC (strain 2))L/8 1/8
H * L * [1* EC (strain 2) )
Table 3
Dilution (ug/ul) of Composition 2
1/4 1/8 1/16 1/32 1/64 1l128 Control
' # 1 2 3 4 5 6 12 IOrganism MIC 1 M80
A * * * * * MSSA 1/8 ‘ <1/4 )
B t * * t * MSSA
C * i * * * * MRSA 1/8 <1/4
{D * * * * * MRSA
E * * * * * EC 1/8 <1/4
F at * * * * EC ‘ ‘
G ‘ * * * * '* EC (strain 2) J 1/8
H * ‘ * * * * EC (strain 2) [:4 |
W0 2012/166655
Table: 4
Dilution (ug/ul) of ition 3
1/32 1/64 1/128 Control 4 [ 5 6 12 Organism MIC MBC
* * * * MSSA 1/16 1/8
* * * * MSSA
* * 1r} MRSA 4 1/16 <1/4
* * * * MRSA
* * * * JEC 1/8 h1/4
* * * * EC
* l * * * EC (strain 2) 1/8 <1/4
* * * *
l j—Eagtrain 2) [
Table 5
Dilution (ug/ul) of Composition 4 1—
114 ' 1/8 1/32 1/64 1l128 Control
# 1 4 5 6 12 Organism MIC MBC
A * * * MSSA '71/64 4 1/16
B * * * MSSA
C * * * MRSA 1/64 1/16
D * 1* JP MRSA
E * * * * EC T1/8 <1/4
F * * * r EC
G * * * * EC (strain 2) ] 1/8 <1/4
H * * * * LEG (strain 2)
Table 6
1l128 1 Control
6 l 12 Organism MIC MBC
* * MSSA 1/16 1/16
* * MSSA
* MRSA 1/16 1 1/16
I * MRSA )
* EC 1/8 1/4
* EC
* l EC n 2) 1/8 1/4
* LEO (strain 2) ‘ ‘
Table 7
1/64 1l128 Control
4 5 6 12 Organism MlC MBC
* * MSSA 1/32 1/16
* * MSSA
* * MRSA 1/32 U16”?
* * MRSA
* * EC 1/8 <1/4
* * EC
* * EC (strain 2) J 1/8 <1/4
* * EC (strain 2)
Table 8
Dilution ) of Composition 7
J T
1/4 1/32 1 1/64 1/128 Control
4 5 6 12 Organism MIC TMBC
j * * MSSA {1/128 1/32
* * MSSA l
* * MRSA 1/128 1/32
* *
J MRSA
* * * EC L1/8 <1/4
~k * * EC IT
* * EC (strain 2) <1/4
L 1* 11/8
* * 1 EC (strain 2) "I
Table 9
’7/4Dilution (ug/ul) of Composition 81/16 [3/32 1/64 1/128 Control
3 4 5 6 12 Organism MIC MBC
* * * * MSSA 1/32 1/8
* i ,r * MSSA ]
* * * * MRSA J 1/32 1/8
* * * * MRSA
* * * * * EC 1 1/16 <1/4
* * r i * EC
* * * * * EC (strain 2) 1/16 <1/4
* h * * * EC (strain 2)
EXAMPLE 2
The compositions provided in Table 10 further illustrate the compositions of the
invention. The “Part A” and “Part B” compositions are intended for use together,
aneously or sequentially in any order. The “Hydrogel” compositions rate single—
part compositions that comprise a gelling agent.
Table 10
PVA PVA
Trisodium Citrate Dihydrate,
Granular, USP 5%
Citric Acid Anhydrous,
Powder USP 2.5%
Methylene Blue Trihydrate
PVA(Elvano|51—05) 25% —_
——-—
__——
_———
*All amounts are expressed as weight tages.
EXAMPLE 3
The following example illustrates additional compositions that can be prepared in
accordance with the invention, as set forth in Tables 11-13.
WO 66655
Table 11
Component Amount
Citrate salt (e.g., trisodium Citrate about 1~50%, about 5—50%,
ate) about 5-30% or about 10-20%
about 0.05—10/0, about 0.05-0.50/0,
Citric Acid or about (Ll—0.3%
Methylene Blue (e.g., ene Blue about 0.005—10/0, about 0.005—0.05%, about
Trihydrate) 0.01—0.050/0, or about 0.01—0.020/0
about 0.1—1%, about 0.1—0.6%,
Methyl—paraben about 0.1—0.5%, or about 0.2—0.3%
about 0.01—1%, about 0.1-0.060/0,
PropyI—paraben about .050/0, or about 0.02—0.030/0 4
Alcohol (e.g., Isopropyl Alcohol) about 0—200/0, about 545%, or about 5—10%
optional film former or thickener (e.g.,
about 0.2-1%, or about 03-05%
Xanthan Gum) j
optional film former or thickener (e.g.,
about 05—10%, or about 1—5%
PVP K60)
optional emollient (e.g., Glycerol) about 1—15%, or about 3-10%
0ptional emollient ( e. g Pro lene
., py
about 1—5%, or about 2—4%
Glycol)
al surfactants and/or foaming
about 0.1—2%, or about 0.1—1%
agents
Water remainder, or about 60—80%
pH about 4—8, or about 6-7
*All amounts expressed as weight percentages.
Table 12
Citrate salt (e.g., trisodium Citrate
Dihydrate) about 0—5% about 5-10%
Citric Acid about 0—1% about 0—1%
Methylene Blue (e.g., Methylene about 0.01-0.10/0, or
Blue Trihydrate) about 0.01—0.050/0
about 0.1-1%, or about
Methyl—paraben 0.050/0-10/0
about 0.1%, or
—paraben about 0.05%-0.1%
about 1-10%, or about
Alcohol (e.g., Isopropyl Alcohol) 2—8%
about 10—40%, or
Polymer (e.g., PVA) about 20—30%
Cross—linking agent (e.g., Borax) — about 1-5%
remainder, or about remainder, or about
Water 60-80% 70-90%
*All amounts are expressed as weight percentages.
2012/039707
Table 13
Citrate salt (e.g., trisodium about 0.1—1%, about 1—10%,
about 1-10%, about 1—5%,
Methylene Blue (e.g.,
Methylene Blue Trihydrate)
Methyl—paraben about 01-05% about 0.1—0.5%
PropyI—paraben about 0.01—0.050/0 about 0.01—0.050/0
Alcohol (e.g., Isopropyl about 30—60%, or about 30-60%,
Alcohol) about 40—50%
about 1—10%,
Gelling agent/thickener (e.g.,
polyacrylic acid, such as about 0.1—1%, or about
ol 674) 5%
Gelling agent/thickener (e.g.,
acrylates mer, such as abOUt 16%
Capigel 98) -
remainder, remainder,
or about 40—60% or about 40—60%
*All amounts are expressed as weight percentages.
EXAMPLE 4
The following example trates the antimicrobial properties of compositions
prepared accordance with the invention.
An in vitro time—kill study was used to evaluate the antimicrobial properties of a
test composition and a positive control product, with and without organic soil loads (FBS
Dilution), when challenged with five American Type e Collection (ATCC)
microorganism strains. The percent and log10 reductions from the initial population of each
challenge species were determined following 30—second, 2—minute, and 5—minute exposures to
the test and positive control compositions. All agar—plating was performed in duplicate. The
test ition contained ium Citrate 10%; Parabens 0.3%; and ene Blue
0.05%. The positive control contained 5000 ppm iodine as an active ingredient. The results
are presented in Tables 14-23, below.
As the s show, the test composition exhibited excellent antimicrobial
properties, which was at least as effective as the positive control composition at most FBS
dilutions against the tested strains.
Table 14
Test ition: No FBS Dilution
Post-
Initial
Microorganism Species_ Exposure Exposure Loglo Percent
Popu a ion1 t‘
_ _ Reduction. (ATCC #) Time Population Reduction.
(CFU/mL)
(CFU/mL)
7.050 x 10 1.4328 96.3089%
Corynebacterium bovis s
1.910 x 10
(ATCC #7715) 2 minutes 4.40 x 10 1.6375 97.6963%
minutes 6.20 x 106 1.4886 96.7539%
< 1.00 x 10 6.0846 99.9999%
ichia coli 1.2150 x seconds
(ATCC #11229) 109 2 minutes < 1.00 x 103 6.0846 99%
minutes < 1.00 x 103 6.0846 99.9999%
1.0150 x 10 3.0408 99.9090%
Pseudomonas aeruginosa 1.1150 x seconds
(ATCC #15442) 109 2 minutes < 1.00 x 103 6.0473 99.9999%
minutes < 1.00 x 103 6.0473 99.9999%
Staphylococcus aureus 30
4.40 x 10 3.2985 99.9497%
aureus 8.750 x 10 seconds
(ATCC #6538) 2 minutes < 1.00 x 103 5.9420 99.9999%
Post—
Initial.
Mlcroorganism s._ Exposure Exposure Loglo Percent
tlon_
(ATCC #) Time Population Reduction Reduction
(CFU/mL)
(CFU/mL)
minutes < 1.00 x 103 5.9420 [ 99.9999%
r" 1
< 1.00 x 103 7.0700 99.9999%
Streptococcus agalactiae 1.1750 x seconds
(ATCC #12386) 1010 2 minutes < 1.00 x 10? 7.0700 1 99.9999%
minutes < 1.00 x 103 7.0700 99.9999%
- 22
Table 15
Positive Control (Iodine): No FBS Dilution
Post-
Initial
Microorganism Spec1es. Exposure Exposure Logm Percent
Po u a ionp 1 t“
ATCC #) Time Population Reduction Reduction
(CFU/mL)
(CFU/mL)
3.550 x 10 1.7308 98.1414%
Corynebacterium bovis seconds
1.910 x 10
(ATCC #7715) 2 s 3.90 x 10 1.6899 97.9581%
minutes 2.440 x 10 1.8936 5%
< 1.00 x 10 6.0846 99.9999%
Escherichia coli 1.2150 x seconds
(ATCC #11229) 109 2 minutes < 1.00 x 10y 6.0846 99.9999%
minutes < 1.00 X 103 6.0846 99.9999%
1.00 x 10 6.0473 99.9999%
Pseudomonas nosa 1.1150 x seconds
(ATCC #15442) 109 2 s < 1.00 x 103 6.0473 99.9999%
minutes < 1.00 x 103 6.0473 99.9999%
Staphylococcus aureus < 1.00 X 10 5.9420 99.9999%
seconds
aureus 8.750 X 108
2 minutes < 1.00 X 10 5.9420 99.9999%
(ATCC #6538)
minutes < 1.00 x 103 5.9420 99.9999%
i
.00 X 10 6.3710 99.9999%
Streptococcus agalactiae 1.1750 x seconds
(ATCC #12386) 1010 2 minutes < 1.00 x 103 7.0700 9%
minutes < 1.00 x 103 7.0700 99.9999%
Table 16
Test Composition: 5% Fetal Bovine Serum
Post—
Initial
Microorganism Species‘ Exposure Exposure Logm Percent
Population .
Population. (ATCC #) Time' Reduction. ion
F
< 1.00 x 10 6.0846 99.9999%
Escherichia coli 1.2150 x seconds
(ATCC #11229) 109 2 minutes < 1.00 x 103 6.0846 99.9999%
minutes < 1.00 x 103 6.0846 99.9999%
1 30
Staphylococcus aureus 4.40 x 10 2.2985 99.4971%
seconds
aureus 8.750 x 10 l. 3
2 minutes I < 1.00 x 10 5.9420 1 99.9999%
(ATCC #6538)
F5 minutes 3
< 1.00 x 10 5.9420 99.9999%
Table 17
Positive Control: 5% Fetal Bovine Serum
Post- l
Initial
Microorganism Species Exposure Exposure Loglo t
Population _
(ATCC #) Time Population Reduction Reduction
(CFU/mL)
(CFU/mL) l
< 1.00 x 10 6.0846 99.9999%
Escherichia coli 1.2150 x seconds
(ATCC #11229) 109 2 minutes < 1.00 x 103 6.0846 9%
minutes < 1.00 x 103 6.0846 99.9999%
Staphylococcus aureas < 1.00 x 10 5.9420 99.9999%
seconds
aureus 8.750 x 10
2 minutes < 1.00 x 10 5.9420 99.9999%
(ATCC #6538) s—
minutes < 1.00 x 10 5.9420 99.9999%
Table 18
Test Compositoin: 10% Fetal Bovine Serum
Post— T
Initial
Microorganism Species. Exposure Exposure Logm t
Population .
. ‘
(ATCC #) Time Population Reductlon Reductlon
(CFU/mL)
(CFU/mL)
2.050 X 10 4.7728 99.9983%
Escherichia coli 1.2150 X seconds Jr
(ATCC #11229) 109 i2 minutes < 1.00 {1.03 6.0846 99.9999%
minutes < 1.00 x 103 6.0846 99.9999%
Staphylococcus aureus 2.270 x 10 1.5860 97.4057%
seconds
aureus 8.750 x 10
2 minutes 7.50 x 10 5.0669 99.9991%
(ATCC #6538) 3
minutes < 1.00 X 10 5.9420 99.9999%
Table 19
Positive Control: 10% Fetal Bovine Serum
Post-
Initial
Microorganism Species Exposure Exposure Loglo Percent
Population'
Population Reduction. (ATCC #) Time Reduction
(CFU/mL)_
(CFU/mL)
< 1.00 X 10 6.0846 99.9999%
Escherichia coli 1.2150 X seconds
(ATCC ) 109 2 minutes J < 1.00 X 103 6.0846 99.9999%
s < 1.00 x 103 6.0846 99.9999%
Staphylococcus aureus 9.90 X 10 2.9464 99.8869%
seconds
aureus 8.750 X 10
2 minutes < 1.00 x 10 5.9420 99.9999%
(ATCC #6538) 3
minutes < 1.00 X 10 5.9420 99.9999%
WO 66655
Table 20
Test Composition: 20% Fetal Bovine Serum
Post—
Initial. .
Microorganism Species‘ Exposure Exposure Loglo Percent
Population. _ .
(ATCC #) Tlme Population Reductlon Reductlon
(CFU/mL)
(CFU/mL) J
1.70 X 10 4.8542 99.9986%
Escherichia coli 1.2150 x seconds
(ATCC #11229) 109 2 minutes < 1.00 x 103 6.0846 99.9999%
1 5 minutes < 1.00 x 103" 6.0846 99.9999%
Staphylococcus aureus 2.2250 X 10 0.5947 74.5714%
aureus 8.750 X 10
‘ 6
2 s H.630 x 10 2.7298 99.8137%
(ATCC #6538) 4
minutes 1.450 X 10 4.7806 99.9983%
Table 21
Positive Control: 20% Fetal Bovine Serum
Post—
Initial
Microorganism Species re Exposure Loglo Percent
Populatlon.
(ATCC #) Time Population Reduction Reduction
(CFU/mL)
(CFU/mL)
2.550 x 10 3.6781 99.9790%
Escherichia 6012' 1.2150 x seconds
(ATCC #11229) 109 2 minutes < 1.00 X 103 6.0846 99.9999%
minutes [< 1.00 x 103 6.0846 99.9999%
Staphylococcus aureus 2.240 x 10 1.5918 0%
seconds
aureus 8.750 X 10
2 minutes < 1.00 X 10 5.9420 99.9999%
(ATCC #6538) r 3
minutes < 1.00 x 10 5.9420 99.9999%
WO 66655
Table 22
Test Composition: 50% Fetal Bovine Serum
Post-
Initial
Microorganism Species Exposure Exposure Logm t
Population
Time' tion. Reduction Reduction_ (ATCC #)
(CFU/mL)
(CFU/mL)
1.7850 x 10 2.8330 99.8531%
Escherichia coli 1.2150 x s
(ATCC #11229) 109 2 minutes 2.00 x 103 5.7836 99.9998%
minutes < 1.00 x 103 6.0846 99.9999%
Staphylococcus aureus 1.0350 x 10 0.0000 0.0000%
seconds
aareus 8.750 X 10
2 minutes 9.750 x 10 0.0000 0.0000%
(ATCC #6538) 8
minutes 4.40 x 10 0.2985 49.7143%
Table 23
Positive Control: 50% Fetal Bovine Serum
Post-
Initial. .
Microorganism Species Exposure Exposure Loglo Percent
Population.
(ATCC #) Time Population. Reduction‘ Reduction
(CFU/mL) [ (CFU/mL)
4.90 x 10 2.3944 99.5967%
Escherichia coli 1.2150 x seconds
(ATCC #11229) 109 2 minutes < 1.00 x 103 6.0846 l 99.9999%
minutes < 1.00 x 103 6.0846 99.9999%
Staphylococcus aurcus 4.050 x 10 0.3345 53.7143%
seconds
aareas 8.750 x 10
2 s 5.30 x 10 1.2177 93.9429%
(ATCC #6538)
L 5
minutes 1.090 x 10 3.9046 99.9875%
The following example illustrates a test for the effectiveness of a composition
prepared in accordance with the invention when used as post—milking teat conditioner.
Test and positive control teat conditioning compositions are applied to the teats of
24 early—mid lactation Jersey cows post-milking. The test compositions contain about 10-20
wt.% trisodium citrate, about 0.2 wt.% citric acid, about 0.2-0.3 wt.% paraben, and various
trations of methylene blue (MB) (about 0.01 wt.%, 0.02 wt.%, and 0.04 wt.%) and
emollient (about 5, 10, and 11 wt.%). The test compositions have formulations similar to the
compositions bed in Example 1, as indicated in Table 24. A positive control
composition contains 1 wt.% iodine and 12 wt.% emollient.
The 24 early—mid lactation Jersey cows are tested in a single pen, with 12 cows
having a blue leg band (BLB group) d to designate them as one trial group and the
other 12 having no leg band (NLB . Left teats ols) of all 24 cows are post dipped
with the control composition, while right side teats are dipped with a test composition. Both
treatment groups are lly dipped with test compositions comprising 0.01% methylene
blue dip (day 0), but having different emollient compositions (5 wt.% v 11 wt.%).
Thereafter, the test compositions are changed to a 0.02 wt.% MB formulation (day 12) to
enhance teat skin coloration. Teats of the NLB group are switched to a 0.04 wt.% MB dip
with 11% emollients (day 21) to potentially further enhance coloration. Teats in the BLB
for the
group are switched to a higher emollient (10 wt. v 5 wt. %) no drip teat dip (day 23)
last week of the trial. A summary of the emollient and MB concentrations is provided in
Table 24. The trial is 4.5 weeks in duration. All other farm and milking practices are similar
across all 4.5 weeks.
Table 24
Blue Le bands BLB N0 Leg Bands (NLB)
M Comp. from Emollient M13 Comp. from ent MB
EX. 1 (wt.%) (wt.%) M EX. 1 (wt.%) (wt.%!
4 5 0.01 0 7 (w/decreased 11 0.01
12 4 5 0.02 12 7 11 0 .02
(w/increased
23 ‘ 8 i 10 0.01 21 7 (w/increased 11 0 .04
2012/039707
Cows are milked twice a day in a double 12 parallel parlor. Cows are forestripped
(3 strips/teat) and pre—dipped (6 cow sequence), then dried with terry cloth towels prior to
milker unit attachment. Automatic detachers are set at 1.8 lb. flow rate and 1 second delay.
A11 cows are housed in a single pen in a free stall barn with mattresses and sawdust shavings
bedding.
Data collection is initiated on Day 1 and continued until Day 30. Test products
are applied at Day 0 at the pm milking with subsequent first data observations the following
am milking on Day 1. Teat coloration (blue coloration due to MB) is evaluated before teat
sanitation / preparation at the subsequent milking after dipping(BP), after premilking teat
sanitation (AP), and after milker unit removal (postmilking — AM) using a 0-2 scale ( 0 = no
color; 1 = light blue; 2 = dark blue). Teat skin and teat end scoring is performed using a
variation of the Goldberg and Timms methods, respectively, by trained graders (Tables 25
and 26). Scoring is performed at both milkings for the first 4 trial days, then three times per
week. Data is entered into an Excel database. Results are ed and analyzed using SAS.
Table 25
Skin ption
Score
0 Teat skin has been subjected to physical injury ( stepped on/ frost bit)
1 Teat skin is , soft and free of any scales, cracks, or chapping.
2 Teat skin shows some evidence of g especially when feeling (areas of
dryness by feeling drag when sliding a gloved hand along the teat barrel &/or
seeing areas of lower ive sheen to the surface of the skin).
3 Teat skin is chapped. Chapping is where visible bits of skin are visibly peeling.
4 Teat skin is chapped and cracked. Redness, indicating inflammation, is t.
Teat skin is severely damaged / ulcerated / open lesions.
Table 26
Teat End Scoring system Degree of hyperkeratosis or callousing
Cracking none minor mild ] te severe
A. No cracking or 1 1.5 2 ‘ 2.5 3
roughness
B. Cracked and / or ——— 3.5 4 4.5 5
rough i
*Zero score tes physical injury of teat.
Mixed procedure of SAS with repeated measured (mixed model with quarter
within cow as a repeated measure) is used to analyze teat skin and teat end data, with p <.05
considered significant. GENMOD procedures of SAS with repeated measures (generalized
linear model with quarter within cow as repeated measure) is used to analyzed %
cracked/rough teat ends and % dry/chapped teat skin data.
During trial week 1 with dips containing 0.01 wt.% methylene blue (MB), an
average of 10-15% of teats show light blue color prior to premilking teat sanitation at next
milking (BP) with 5% emollient dips showing higher results compared to 11% emollient, and
minimal to no teat coloration after premilking teat sanitation (AP) or after milking (AM).
Teats dipped with products containing 0.02 wt.% MB show a higher percentage of teat
coloration BP (40-50%) and 11 wt.% emollient dipped teats show higher coloration AP
(25%) and AM (10%). Teats dipped with 0.04 wt.% MB show no coloration age to
0.02 wt.% MB. Teats dipped with 0.01 wt.% MB and a thixotropic agent (no drip) show
comparable results to 0.02 wt.% MB.
Temperature 5—10 days pretrial is cold (00F) followed by 8 days @ 20°F. Then
there are 2 days @ 05°F, 3 days @ 20°F, then 4 days @ 0°F ( —10°F minimum temps.) (1st 4
days trial week 2). Trial weeks 3 (40°F) and 4 (250F) are seasonably high for winter.
With t to teat skin integrity, there is no difference in TE scores and integrity
across treatment and control dips and all time periods. 99+% teats showed excellent teat skin
health (score 1).
With respect to teat end integrity, control and treatment dipped teats are not
significantly different during trial week one (average TE scores or % rough / d teats).
Control teats have significantly higher TE scores and % rough / cracked TE compared to
treatment teats during trial weeks 2—3 (BLB .. 5% ent) and trial week 2 (elevated
insignificantly in week 3) (NLB — 11% emollients); and insignificantly higher in trial week 4.
Treatment dipped teats with 5% emollient have more consistent TE results ed to 11%
emollient, but caution should be sed in interpretations as cows were ent.
These results Show that the test compositions provide some teat coloration at next
milking. Furthermore, the test compositions e excellent teat skin (TS) health as
compared to the positive control, excellent teat end health integrity as compared to the
positive control, and maintain teat end health integrity through cold weather changes
significantly better than controls. Dips with 5 wt.% emollient provide consistent TE health
compared, and the test ition dips e softer, more pliable hyperkeratotic TE tissue
than comparative dips.
All references, including publications, patent applications, and patents, cited
herein are hereby incorporated by reference to the same extent as if each reference were
individually and specifically indicated to be incorporated by reference and were set forth in
its entirety herein.
The use of the terms “a” and “an” and “the” and similar referents in the context of
describing the ion ially in the context of the ing claims) are to be
construed to cover both the singular and the plural, unless otherwise indicated herein or
clearly contradicted by context. The terms “comprising,” g,” “including,” and
ining” are to be construed as open—ended terms (i.e., meaning “including, but not
limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely
intended to serve as a shorthand method of ing individually to each separate value
falling within the range, unless otherwise indicated , and each separate value is
incorporated into the specification as if it were dually recited herein. All methods
described herein can be performed in any le order unless ise indicated herein or
otherwise clearly contradicted by context. The use of any and all examples, or exemplary
language (e. g., “such as”) provided herein, is intended merely to better illuminate the
invention and does not pose a limitation on the scope of the ion unless otherwise
claimed. No language in the specification should be construed as indicating any non—claimed
t as essential to the practice of the invention.
red embodiments of this invention are described herein, including the best
mode known to the inventors for carrying out the invention. Variations of those preferred
embodiments may become apparent to those of ordinary skill in the art upon reading the
foregoing description. The inventors expect skilled artisans to employ such variations as
appropriate, and the inventors intend for the invention to be practiced otherwise than as
specifically described herein. Accordingly, this invention includes all modifications and
equivalents of the subject matter recited in the claims appended hereto as permitted by
applicable law. Moreover, any combination of the described elements in all possible
variations thereof is encompassed by the invention unless otherwise indicated herein or
otherwise clearly contradicted by context.
Claims (55)
1. Use of a topical ition comprising (a) e; (b) methylene blue; and (c) an alkyl para-hydroxybenzoate; in the manufacture of a medicament for treating or protecting against mastitis or drying, chapping, or cracking of the skin of a mammalian teat.
2. The use of claim 1, wherein the topical composition comprises: (a) 0.1-2 M citrate; (b) 0.1-3 mM methylene blue; and (c) 10-50 mM alkyl para-hydroxybenzoate.
3. The use of claim 1 or claim 2, wherein the topical composition comprises 0.005-0.5 wt.% ene blue.
4. The use of any one of claims 1-3, n the topical composition comprises methyl para-hydroxybenzoate, propyl para-hydroxybenzoate, or both.
5. The use of any one of claims 1-4, wherein the topical composition further comprises alcohol.
6. The use of claim 5, wherein the alcohol is isopropyl alcohol.
7. The use of claim 5 or claim 6, n the l composition comprises 0.1 % to 20 % alcohol.
8. The use of any one of claims 1-7, wherein the topical composition further comprises an emollient.
9. The use of claim 8, wherein the topical composition comprises 5 wt.% or more of an emollient.
10. The use of claim 8 or claim 9, wherein the emollient comprises glycerol, propylene glycol, a lanolin or a combination thereof.
11. The use of any one of claims 1-10, wherein the topical composition further comprises a surfactant, a thickener, or a film-forming agent.
12. The use of any one of claims 1-11, n the topical composition further comprises e or ascorbic acid.
13. The use of any one of claims 1-12, wherein the topical composition further comprises sodium at a concentration of 0.3 M or more.
14. The use of any one of claims 1-13, wherein the pH of the topical composition is 4-8.
15. The use of any one of claims 1-14, wherein the topical composition has a kinimatic viscosity of 50 cP or more measured at 25 oC and 1 atm pressure.
16. The use of any one of claims 1-15, wherein the topical composition is a liquid, gel, or foam.
17. The use of any one of claims 1-16, wherein the topical composition provides an antimicrobial effect.
18. The use of any one of claims 1-17, wherein the mammal is a roducing .
19. A two-part topical composition comprising: (a) a first topical composition comprising a polymer; and (b) a second topical composition comprising a cross-linking agent for the polymer; whereby a protective coating is provided when applied to a non-human teat; n the polymer comprises polyvinyl alcohol, polyvinyl acetate, N-alkyl pyrrolidone, ter phthalate, polyester sebacat, or yl litate; and wherein the first or second topical composition, or both, comprises methylene blue.
20. The two-part topical composition of claim 19, wherein the first or second topical composition, or both, comprises citrate.
21. The two-part topical composition of claim 19 or claim 20, wherein the first or second topical composition, or both, comprises an alkyl para-hydroxybenzoate.
22. The two-part topical ition of any one of claims 19-21, wherein the first or second topical composition, or both, comprises alcohol.
23. The two-part topical composition of any one of claims 19-22, wherein the polymer is polyvinyl alcohol.
24. The two-part l composition of claim 23, wherein the linking agent is borate.
25. The two-part topical composition of claim 19, wherein the first topical composition comprises citrate, methylene blue, and polyvinyl l, and the second topical composition comprises citrate, an alkyl para-hydroxybenzoic acid, alcohol, and borax.
26. The two-part topical composition of claim 25, wherein the first topical ition comprises (a) citrate; (b) 0.01-2 mM or 0.1-1 mM methylene blue; and (c) 5-50 wt.% nyl alcohol; and the second topical ition comprises (a) 0.2-1 M citrate; (b) 20-100 mM alkyl para-hydroxybenzoate; (c) 1-10 % alcohol; and (d) borax.
27. A method of treating or protecting a non-human mammalian teat comprising applying a topical composition to the teat, wherein the topical composition comprises (a) citrate; (b) methylene blue; and (c) an alkyl para-hydroxybenzoate.
28. The method of claim 27, wherein the topical composition comprises: (a) 0.1-2 M citrate; (b) 0.1-3 mM methylene blue; and (c) 10-50 mM alkyl para-hydroxybenzoate.
29. The method of claim 27 or claim 28, wherein the topical composition comprises 0.005- 0.5 wt.% methylene blue.
30. The method of any one of claims 27-29, wherein the l composition comprises methyl para-hydroxybenzoate, propyl para-hydroxybenzoate, or both.
31. The method of any one of claims 27-30, wherein the topical composition r comprises l.
32. The method of claim 31, wherein the alcohol is isopropyl alcohol.
33. The method of claim 31 or claim 32, wherein the topical composition ses 0.1 % to 20 % alcohol.
34. The method of any one of claims 27-33, wherein the topical composition further comprises an emollient.
35. The method of claim 34, wherein the topical composition comprises 5 wt.% or more of an emollient.
36. The method of claim 34 or claim 35, wherein the emollient comprises ol, propylene glycol, a lanolin or a combination thereof.
37. The method of any one of claims 27-36, wherein the l composition further comprises a tant, a thickener, or a film-forming agent.
38. The method of any of claims 27-37, wherein the topical ition further comprises anolyte or ascorbic acid.
39. The method of any one of claims 27-38, wherein the topical ition further comprises sodium at a concentration of 0.3 M or more.
40. The method of any one of claims 27-39, wherein the pH of the topical composition is 4-
41. The method of any one of claims 27-40, wherein the topical composition has a kinimatic viscosity of 50 cP or more measured at 25 oC and 1 atm pressure.
42. The method of any one of claims 27-41, wherein the topical composition is a liquid, gel, or foam.
43. The method of any one of claims 27-42, wherein the topical composition provides an antimicrobial effect.
44. The method of any one of claims 27-43, wherein the mammal is a food-producing animal.
45. A method of treating or protecting a non-human mammalian teat comprising applying to the teat: (a) a first topical composition comprising a polymer; and (b) a second topical composition comprising a cross-linking agent for the polymer; whereby a protective g is provided on the teat; wherein the polymer comprises polyvinyl alcohol, nyl acetate, N-alkyl pyrrolidone, ter phthalate, polyester sebacat, or trioctyl trimellitate; and wherein the first or second topical composition, or both, comprises methylene blue.
46. The method of claim 45, wherein the first or second topical composition, or both, comprises citrate.
47. The method of claim 45 or claim 46, n the first or second topical composition, or both, comprises an alkyl para-hydroxybenzoate.
48. The method of any one of claims 45-47, wherein the first or second topical composition, or both, comprises alcohol.
49. The method of any one of claims 45-48, wherein the r is polyvinyl alcohol.
50. The method of claim 49, wherein the cross-linking agent is borate.
51. The method of claim 45, wherein the first topical composition comprises citrate, methylene blue, and polyvinyl alcohol, and the second topical composition comprises citrate, an alkyl ydroxybenzoic acid, alcohol, and borax.
52. The method of claim 45, wherein the first topical composition comprises (a) citrate; (b) 0.01-2 mM or 0.1-1 mM methylene blue; and (c) 5-50 wt.% polyvinyl alcohol; and the second topical composition ses (a) 0.2-1 M citrate; (b) 20-100 mM alkyl para-hydroxybenzoate; (c) 1-10 % alcohol; and (d) borax.
53. The method of any one of claims 27-52, wherein the method is for treating or protecting the health or condition of the skin of a non-human mammalian teat.
54. The method of claim 53, wherein the method is for ng or protecting against dryness, chapping, or cracking of the skin of a mammalian teat.
55. The method of any one of claims 27-52, wherein the method is for treating or protecting against is in the non-human mammalian teat. Zurex PharmAgra, Inc. By the patent attorneys for the applicant CULLENS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/491,053 | 2011-05-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ619207A true NZ619207A (en) | 2016-12-23 |
NZ619207B2 NZ619207B2 (en) | 2017-03-24 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10098908B2 (en) | Method of treating a mammalian teat and related compositions | |
US8772341B2 (en) | Compositions for the treatment of hoof diseases | |
US8043626B2 (en) | Fatty acid antimicrobial | |
CN104884044B (en) | Bactericidal composition containing mixture of carboxylic acids and the application as partly sterilised's agent | |
WO1981001516A1 (en) | Control of mastitis and compositions therefor | |
EP3060040B1 (en) | Antimicrobial compositions | |
AU740138B2 (en) | Disinfecting composition | |
US20120177747A1 (en) | Compositions and Methods for Treating Lameness in Hoofed Domesticated Animals Due to Hairy Foot Warts and Foot Rot | |
AU2009304000B2 (en) | Anti-infective formulation and methods of use | |
US9855205B2 (en) | Use of zinc coceth sulfate as an antibacterial agent against propionibacterium acnes | |
NZ619207A (en) | Method of treating a mammalian teat and related compositions | |
NZ619207B2 (en) | Method of treating a mammalian teat and related compositions | |
AU2015202929B2 (en) | Anti-infective formulation and methods of use | |
EP3366279A1 (en) | Disinfectant and film-forming composition intended for being applied after milking a teat, containing lactic acid |